Professor Daniel Qiang Fu 付强
Longevity Scientist · Biotech Entrepreneur · MR Longevity Founder
China · UK · Global
Science, translated into healthier lives
Professor Daniel Qiang Fu is a scientist and biotechnology entrepreneur working to understand the biology of ageing and translate scientific discoveries into practical solutions for healthier, longer lives.
His research spans cellular senescence, NK-cell immunology, reproductive immunology, stem-cell and ovarian biology, exosomes, cancer, and the use of biomarkers and AI in ageing. Alongside fundamental science, his focus is increasingly translational: identifying promising interventions, validating them rigorously, and creating pathways through which research becomes technologies, products and health solutions.
As founder of MR Longevity, his wider ambition is to build an international mission connecting science, people, technology, healthcare, data and investment to accelerate progress in healthy longevity.
20+
SCI papers as first or corresponding author
2
Scientific monographs
8
Granted patents
As reported by Binzhou Medical University, June 2024.
Where the work sits
From mechanisms of ageing to the technologies and evidence needed to apply them.
Professor & Postgraduate Supervisor
Institute of Aging Medicine · School of Pharmacy, Binzhou Medical University (Yantai)
Listed in the university's Aging Medicine Innovation Team.
SourceShandong Cellogene
Company affiliation listed on peer-reviewed publications
Academic–industry bridge for NK-cell and stem-cell technologies.
Founder, MR Longevity
Global healthy longevity mission
Connecting science, healthcare, innovation, capital, data and AI.
Former Postdoctoral Researcher
University of North Carolina (UNC), United States
Selected peer-reviewed record
Publications from 2014 to 2025.
Translated technology
Granted patents in NK-cell manufacturing, exosome compositions and diagnostics.
Simple device for efficient expansion of peripheral-blood NK cells
ZL201711290960.6 · Granted 4 May 2021
Core NK-cell manufacturing process technology; licensed in 2022.
Mesenchymal stem-cell exosomes and compositions, cosmetic applications
ZL202111445023.X · Granted 10 October 2023
Biological materials and cosmetic applications; transferred in 2024.
Automated NK-cell culture device
ZL20230548727.8 · Utility model, granted 18 August 2023
Automation supporting scalable NK-cell production; transferred in 2024.
NK-cell activity detection kit
Authorised patent transfer reported 2022
Diagnostic assay for NK-cell activity.
Funded research programmes
National and provincial research funding supporting the work.
LAIRs' regulation of decidual NK-cell functional development in early pregnancy
National Natural Science Foundation of China · 81370730
RMB 660,000 · 2014–2017
STAT-mediated regulation of decidual NK-cell functional development
National Natural Science Foundation of China · 81571512
RMB 700,000 · 2016–2019
Provincial research programme
Shandong Natural Science Foundation · ZR2023MH262
Acknowledged in 2024–25 publications.
Yantai Double Hundred Program
Talent and research support
Cited in senomorphic therapeutics research.
University–locality collaborative programme
2021XDHZ082
Collaborative research funding.
Build the healthy longevity mission
Researchers, clinicians, innovators, investors and partners, collaborate on projects inside MR Longevity.